What Lightox does

LightOx Limited is a UK-based biotechnology company founded in 2016 as a spin-out from Durham University, developing light-activated drug compounds for therapeutic and research applications. Its core technology uses proprietary photosensitizing agents that remain inactive until exposed to specific wavelengths of light, at which point they generate reactive oxygen species to selectively destroy targeted cells while sparing surrounding healthy tissue. The company is organized around two lead therapeutic candidates: LXD191, a topical oral gel for the treatment of oral epithelial dysplasia (a precancerous mouth lesion) that is activated by dental curing lights and is advancing toward Phase I/IIa clinical trials; and LXD231, a light-activated wound care gel targeting antibiotic-resistant bacterial infections, including battlefield applications under NATO DIANA programme support. LightOx also markets a portfolio of research tools, including fluorescent imaging probes, the PhotoReact light-activated research reagent, and a UV Luminator prototype developed through the CPI Spotlight programme.

The business model is a pre-revenue pharmaceutical licensing model, with future revenue expected from milestone payments and royalties on licensed drug candidates rather than direct product sales. LightOx is currently raising £10 million to fund Phase I/IIa clinical trials beginning in 2026 and is targeting partnerships with pharmaceutical companies and clinical institutions, with particular interest in Asian markets where oral cancer incidence is higher. The company is supported by an ecosystem of UK-based clinical and academic partners, including the Liverpool Head and Neck Centre, University College London, the Centre for Process Innovation, Medicines Discovery Catapult, and a syndicate of seed and grant investors led by Northstar Ventures, Praetura's GMC Life Sciences Fund, and Innovate UK. LightOx operates from its headquarters at 65 Westgate Road in Newcastle upon Tyne, with laboratories at the Biosphere facility, and maintains a team of approximately 15-20 people.

Name

Lightox

Legal name

LIGHTOX LIMITED

Website

https://lightox.co.uk

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

LightOx is a UK biotech, spun out of Durham University in 2016, developing light-activated drug compounds for treating oral epithelial dysplasia (LXD191) and antibiotic-resistant wound infections (LXD231), with lead candidate entering Phase I/IIa clinical trials in 2026.

Ownership category

akta.pro rank

Product category

Photodynamic Therapy Pharmaceuticals

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Medicinal Chemicals & Botanical Products (2833), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Wound & Ostomy Skin Care (Barrier Films/Creams, Adhesive Removers, Cleansers) (HLAHALAK)

Keywords

• Photodynamic therapy
• Light-activated drugs
• Oral cancer treatment
• Wound care therapy
• Fluorescent imaging probes

Headquarters

HQ city

Billingham

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Licensing and Royalties: Pre-revenue biotech company. Future revenue expected from licensing drug candidates to pharmaceutical partners, with potential milestone payments and royalties on sales.
2. Direct Pharmaceutical Sales: Potential direct commercialization of approved light-activated drug products through traditional pharmaceutical distribution channels in target markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

LightOx develops proprietary light-activated drug compounds (photosensitising agents) that remain inactive until exposed to specific wavelengths of light, then generate reactive oxygen species to selectively destroy diseased cells. Its lead candidate LXD191 is a topical oral gel activated by dental curing lights to treat oral epithelial dysplasia (a precancerous condition), and LXD231 is a light-activated gel for wound care targeting antibiotic-resistant infections. The company also supplies fluorescent imaging probes and light-activated research tools for scientific applications.

Product overview

LightOx is a life sciences company developing light-activated drug compounds for therapeutic applications. The company operates with a portfolio approach, with two lead therapeutic candidates: LXD191 (light-activated oral gel for early-stage oral cancer treatment) and LXD231 (light-activated wound care gel for infection control). Additionally, LightOx offers research tools including imaging probes (PhotoReact) and fluorescent probes for scientific research applications. The technology platform uses photosensitising agents combined with light activation to target and kill diseased cells while preserving surrounding healthy tissue.

Differentiator

Problem solved

Functional benefit

Brands

• LIGHTOX Therapeutics: Therapeutics brand for LightOx's drug development pipeline including oral cancer and wound care treatments

Products and services

• LXD191

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Durham UniversitycoreStrategic or Co-development PartnerAcademic institution from which LightOx was spun out. Ongoing research collaboration with university researchers for technology development.
• Liverpool Head and Neck CentrecoreStrategic or Co-development PartnerClinical collaboration partnership for developing and testing light-activated treatments for oral cancer and precancerous conditions in head and neck applications.
• Centre for Process Innovation (CPI)coreStrategic or Co-development PartnerCollaboration with CPI for formulation development of drug compounds, leveraging CPI's expertise in pharmaceutical development and scale-up.
• University College LondoncoreStrategic or Co-development PartnerAcademic research collaboration with UCL researchers for advancing light-activated drug technology and clinical applications.
• Medicines Discovery Catapult (MDC)minorStrategic or Co-development PartnerAccelerator and support program providing access to drug discovery expertise and resources for LightOx's development programs.
• NATO DIANAcoreStrategic or Co-development PartnerSelected for NATO DIANA 2026 accelerator cohort in the Human Resilience and Biotechnology challenge area, providing access to defense and security innovation networks and potential funding.
• Ryder ArchitectureminorOthersProperty consultation for office and facility requirements.
• Naylors Gavin BlackminorOthersProperty consultants providing assistance with commercial property matters.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Ondine Biomedical: Developer of antimicrobial photodynamic therapy (Steriwave nasal decolonisation) using a light-activated porphyrin to kill resistant bacteria. Directly comparable to LightOx's LXD231 wound care programme targeting antibiotic-resistant infections with a light-activated compound.
• Theralase Technologies: Developer of photodynamic therapy (TLD-1433) for non-muscle invasive bladder cancer, activated by a green laser. Closely comparable to LightOx in mechanism (photosensitiser + light), indication class (oncology), and early-clinical stage.
• Steba Biotech: Developer of Tookad (padeliporfin), a vascular-targeted photodynamic therapy for low-risk prostate cancer. Directly comparable as a photosensitiser-plus-laser company in oncology with a similar regulatory pathway in EU/UK.
• Biofrontera: Commercial-stage photodynamic therapy company selling Ameluz (aminolevulinic acid) for actinic keratosis and basal cell carcinoma, activated by a BF-RhodoLED lamp. Most directly comparable commercial peer to LightOx's photosensitiser-plus-light modality, with shared regulatory and clinical translation challenges.
• Photocure ASA: Commercial Norwegian company selling Hexvix/Cysview, a porphyrin-based photosensitiser for photodynamic diagnosis of bladder cancer. Comparable as a revenue-generating photodynamic therapy/diagnostics company in a similar oncology-adjacent specialty.
• DUSA Pharmaceuticals: Pioneer of Levulan (aminolevulinic acid) photodynamic therapy for actinic keratosis, acquired by Sun Pharma. Highly comparable reference point for LightOx's pathway from pre-clinical photosensitiser to commercial PDT product.

Broad incumbents

• MolecuLight: Commercial-stage wound imaging company using fluorescence to detect bacteria in wounds. Adjacent to LightOx's wound care mission (LXD231) and a useful comparator for clinical adoption of light-based wound care tools, though focused on diagnostics rather than treatment.

Emerging players

• Kura Oncology: US oncology biotech with a lead programme (tipifarnib) targeting HRAS-mutant head and neck squamous cell carcinoma, including oral cancer indications. Comparable as a small-cap oral/head-and-neck cancer specialist with similar clinical-development profile.
• Lumibird Medical: Medical laser manufacturer supplying clinical laser systems used in ophthalmology and photodynamic therapy delivery. Comparable as a provider of the light-delivery hardware that underpins light-activated therapeutics like LightOx's pipeline.

Regional players

• e-Therapeutics: UK-based preclinical-stage biotech developing computational approaches to drug discovery. Comparable as a UK early-stage life sciences peer facing similar capital-raise dynamics and regulatory pathway, though with a different therapeutic modality.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lightox